<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01874470</url>
  </required_header>
  <id_info>
    <org_study_id>Allegro-HTN</org_study_id>
    <nct_id>NCT01874470</nct_id>
  </id_info>
  <brief_title>Renal Denervation by Allegro System in Patients With Resistant Hypertension</brief_title>
  <official_title>Renal Denervation by Allegro System in Patients With Resistant Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai AngioCare Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai AngioCare Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of ALLEGRO-HTN trial is to evaluate the safety and effectiveness of renal
      denervation in subjects with resistant hypertension by using Allegro renal denervation system
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in office-based systolic blood pressure (SBP) from baseline to 6 months</measure>
    <time_frame>6 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in average 24-hour SBP by ambulatory blood pressure monitoring (ABPM) from baseline to 6 months</measure>
    <time_frame>6 month</time_frame>
    <description>Change in average 24-hour SBP by ambulatory blood pressure monitoring (ABPM) from baseline to 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• The incidence of major adverse events (MAE) at 1 month postrandomization</measure>
    <time_frame>1-month post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Office SBP and DBP at 1, 3, 6 months postrandomization</measure>
    <time_frame>up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Patient-recorded home systolic blood pressure at 1, 3, 6 months postrandomization</measure>
    <time_frame>up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• MAE at 6-month post-randomization, including new renal artery stenosis &gt;60%</measure>
    <time_frame>up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Renal Denervation</condition>
  <condition>Resistant Hypertension</condition>
  <condition>Standard Medication</condition>
  <arm_group>
    <arm_group_label>standard medication</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard Medication: Continued usage of 3 or more antihypertensive medications of different classes, including a diuretic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>renal denervation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allegro Renal Denervation System (AngioCare)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>renal denervation</intervention_name>
    <arm_group_label>renal denervation</arm_group_label>
    <other_name>Allegro Renal Denervation System (AngioCare)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard medication</intervention_name>
    <arm_group_label>standard medication</arm_group_label>
    <arm_group_label>renal denervation</arm_group_label>
    <other_name>Standard Medication: Continued usage of 3 or more antihypertensive medications of different classes, including a diuretic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 - 65 years at time of randomization

          -  Stable medication regimen including 3 or more antihypertensive medications of
             different classes, including a diuretic (with no changes for a minimum of 4 weeks
             prior to screening) and no expected changes for at least 6 months

          -  1) Office SBP and/or DBP ≥160/100 mm Hg ( ≥ 150/95 mmHg for type II diabetic patients)
             , 2) ABPM 24 hour average SBP and/or DBP ≥140 and/or 90 mmHg

          -  Main renal arteries with ≥4 mm diameter or with ≥20 mm treatable length (by visual
             estimation)

          -  eGFR≥45 mL/min/1.73 m2

          -  Written informed consent

        Exclusion Criteria:

          -  Type 1 diabetes mellitus

          -  Secondary hypertension

          -  Has an implantable cardioverter defibrillator (ICD) or pacemaker

          -  Myocardial infarction, unstable angina pectoris, syncope, or a cerebrovascular
             accident within 6 months of the screening period

          -  Intravascular thrombosis or unstable atherosclerotic plaques

          -  Has hemodynamically significant valvular heart disease

          -  Pregnant, nursing, or planning to be pregnant

          -  Any serious medical condition that may adversely affect the safety of the participant
             or the study

          -  Currently enrolled in another investigational drug or device trial

        Angiographic Exclusion Criteria:

          -  Renal artery stenosis (≥50%) or renal artery aneurysm in either renal artery

          -  History of prior renal artery intervention including balloon angioplasty or stenting

          -  Multiple renal arteries where the main renal artery is estimated to supply &lt;75% of the
             kidney

          -  Main renal arteries with &lt;4 mm diameter or with &lt;20 mm treatable length (by visual
             estimation)

          -  Renal artery abnormalities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fuwai hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2013</study_first_submitted>
  <study_first_submitted_qc>June 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2013</study_first_posted>
  <last_update_submitted>October 19, 2016</last_update_submitted>
  <last_update_submitted_qc>October 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diuretics</mesh_term>
    <mesh_term>Antihypertensive Agents</mesh_term>
    <mesh_term>Frovatriptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

